HRP20220464T1 - Derivati 5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(1h-pirazol-1-il)pirazolo[1,5-a]pririmidina i srodni spojevi kao inhibitori trk kinaze za liječenje raka - Google Patents
Derivati 5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(1h-pirazol-1-il)pirazolo[1,5-a]pririmidina i srodni spojevi kao inhibitori trk kinaze za liječenje raka Download PDFInfo
- Publication number
- HRP20220464T1 HRP20220464T1 HRP20220464TT HRP20220464T HRP20220464T1 HR P20220464 T1 HRP20220464 T1 HR P20220464T1 HR P20220464T T HRP20220464T T HR P20220464TT HR P20220464 T HRP20220464 T HR P20220464T HR P20220464 T1 HRP20220464 T1 HR P20220464T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyrazolo
- pyrrolidin
- pyrazol
- difluorophenyl
- pyrimidine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 21
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 201000011510 cancer Diseases 0.000 title claims 2
- FWDOVLGKHCXRFF-UHFFFAOYSA-N FC1=C(C=C(C=C1)F)C1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC=C1 Chemical class FC1=C(C=C(C=C1)F)C1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC=C1 FWDOVLGKHCXRFF-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 12
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- BXMJUVFWPZJJBT-HXUWFJFHSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-(4-pyrimidin-5-ylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C=NC=NC=1 BXMJUVFWPZJJBT-HXUWFJFHSA-N 0.000 claims 4
- GWBKXZDPLGYFKL-GOSISDBHSA-N FC=1C(=NC(=CC=1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=CC=NC=C1 Chemical compound FC=1C(=NC(=CC=1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=CC=NC=C1 GWBKXZDPLGYFKL-GOSISDBHSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 2
- OXLGFSVYEYBBDZ-LJQANCHMSA-N 1-[1-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-4-yl]-N,N-dimethylmethanamine Chemical compound C=1(C=NN(C=1)C1=C2N=C(N3[C@H](CCC3)C3=C(C=CC(F)=C3)F)C=CN2N=C1)CN(C)C OXLGFSVYEYBBDZ-LJQANCHMSA-N 0.000 claims 2
- YAQRMLFNKOAITD-GOSISDBHSA-N 1-[1-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-4-yl]ethanone Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C(C)=O YAQRMLFNKOAITD-GOSISDBHSA-N 0.000 claims 2
- LSXIREPWFJYMCM-UUSAFJCLSA-N 1-[1-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-4-yl]pyrrolidin-3-ol Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)N1CC(CC1)O LSXIREPWFJYMCM-UUSAFJCLSA-N 0.000 claims 2
- HHRDXXMUPDELIS-UHUGOGIASA-N 1-[1-[5-[(2R)-2-(3-fluoropyridin-2-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-4-yl]pyrrolidin-3-ol Chemical compound FC=1C(=NC=CC=1)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)N1CC(CC1)O HHRDXXMUPDELIS-UHUGOGIASA-N 0.000 claims 2
- NRNPLYYLKPVNIC-GOSISDBHSA-N 2-[1-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-4-yl]-5-methyl-1,3,4-oxadiazole Chemical compound CC1=NN=C(O1)C1=CN(N=C1)C1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1 NRNPLYYLKPVNIC-GOSISDBHSA-N 0.000 claims 2
- XPNRQOFDSVATHP-GOSISDBHSA-N 2-[1-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-4-yl]ethanol Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)CCO XPNRQOFDSVATHP-GOSISDBHSA-N 0.000 claims 2
- YPELMYCNROOBTL-GOSISDBHSA-N 2-[1-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-4-yl]propan-2-ol Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C(C)(C)O YPELMYCNROOBTL-GOSISDBHSA-N 0.000 claims 2
- HBLSATXZAMOVSK-HXUWFJFHSA-N 3-(4-diethylphosphorylpyrazol-1-yl)-5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)P(CC)(CC)=O HBLSATXZAMOVSK-HXUWFJFHSA-N 0.000 claims 2
- XMVDTTWJPOUEQE-CQSZACIVSA-N 3-(4-methylpyrazol-1-yl)-N-[(1R)-1-phenylethyl]pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound C[C@@H](NC1=NC2=C(C=NN2C=C1)N1C=C(C)C=N1)C1=CC=CC=C1 XMVDTTWJPOUEQE-CQSZACIVSA-N 0.000 claims 2
- DTSSISWXVSDVEG-GOSISDBHSA-N 3-[1-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-4-yl]-1,1-bis(methylsulfonyl)urea Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)NC(N(S(=O)(=O)C)S(=O)(=O)C)=O DTSSISWXVSDVEG-GOSISDBHSA-N 0.000 claims 2
- BJWFEKVBDBMJOM-GOSISDBHSA-N 3-[1-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-4-yl]-1,1-dimethylurea Chemical compound CN(C)C(=O)NC1=CN(N=C1)C1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1 BJWFEKVBDBMJOM-GOSISDBHSA-N 0.000 claims 2
- OFCFPJTYMSVMDW-OAQYLSRUSA-N 4-[1-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-4-yl]-1-methylpyridin-2-one Chemical compound CN1C=CC(=CC1=O)C1=CN(N=C1)C1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1 OFCFPJTYMSVMDW-OAQYLSRUSA-N 0.000 claims 2
- SKMQZCZYTWTLGJ-OAQYLSRUSA-N 4-[1-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-4-yl]pyridine-3-carboxamide Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=CC=NC=C1C(=O)N SKMQZCZYTWTLGJ-OAQYLSRUSA-N 0.000 claims 2
- DOAYPAWWMMRURC-QGZVFWFLSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-(3-methoxy-5-methylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=C(C=C1C)OC DOAYPAWWMMRURC-QGZVFWFLSA-N 0.000 claims 2
- IQIWFTJAEREFNO-GOSISDBHSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-(4-dimethylphosphorylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)P(C)(C)=O IQIWFTJAEREFNO-GOSISDBHSA-N 0.000 claims 2
- ATDSJVXRQZIOOZ-OAQYLSRUSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-(4-pyridin-3-ylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C=NC=CC=1 ATDSJVXRQZIOOZ-OAQYLSRUSA-N 0.000 claims 2
- OAUDLINPJVTIOT-HXUWFJFHSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-(4-thiophen-3-ylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=CSC=C1 OAUDLINPJVTIOT-HXUWFJFHSA-N 0.000 claims 2
- KHJVGVHRRPXITB-QGZVFWFLSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-(5-methoxy-3-methylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=C(C=C1OC)C KHJVGVHRRPXITB-QGZVFWFLSA-N 0.000 claims 2
- BLMHXOHJXHHGKN-HXUWFJFHSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(1-methylpyrazol-4-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C=NN(C=1)C BLMHXOHJXHHGKN-HXUWFJFHSA-N 0.000 claims 2
- PWEYRABKJOCWSK-HXUWFJFHSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(2,3-dihydrofuran-4-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=COCC1 PWEYRABKJOCWSK-HXUWFJFHSA-N 0.000 claims 2
- UCWVSDYBOZWXFP-HXUWFJFHSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(2,5-dihydrofuran-3-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1COCC=1 UCWVSDYBOZWXFP-HXUWFJFHSA-N 0.000 claims 2
- LOCNSQYFFCGBPX-HXUWFJFHSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(2-fluoropyridin-3-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C(=NC=CC=1)F LOCNSQYFFCGBPX-HXUWFJFHSA-N 0.000 claims 2
- FFTGLCWKKQORHP-OAQYLSRUSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(2-methoxypyridin-3-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C(=NC=CC=1)OC FFTGLCWKKQORHP-OAQYLSRUSA-N 0.000 claims 2
- DQGUCFPJMFZLHZ-OAQYLSRUSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(3,6-dihydro-2H-pyran-4-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C2=CCOCC2)=C(F)C=C1 DQGUCFPJMFZLHZ-OAQYLSRUSA-N 0.000 claims 2
- QHTQEWAPKMFSPJ-OAQYLSRUSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(3-fluoropyridin-4-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=C(C=NC=C1)F QHTQEWAPKMFSPJ-OAQYLSRUSA-N 0.000 claims 2
- IEPYMPGIRKJHES-OAQYLSRUSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(3-methoxypyridin-4-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=C(C=NC=C1)OC IEPYMPGIRKJHES-OAQYLSRUSA-N 0.000 claims 2
- OCNIPDJFQKXOFH-OAQYLSRUSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(4-methoxypyridin-3-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C=NC=CC=1OC OCNIPDJFQKXOFH-OAQYLSRUSA-N 0.000 claims 2
- LAJRAXPLWKKACO-OAQYLSRUSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(6-methoxypyridin-3-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C=NC(=CC=1)OC LAJRAXPLWKKACO-OAQYLSRUSA-N 0.000 claims 2
- FSERQXAZXYLBNL-GOSISDBHSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(methoxymethyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)COC FSERQXAZXYLBNL-GOSISDBHSA-N 0.000 claims 2
- WQJAFTXYVSMMQO-OAQYLSRUSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(oxan-4-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1CCOCC1 WQJAFTXYVSMMQO-OAQYLSRUSA-N 0.000 claims 2
- OAKZLEZKMVHSHC-LJQANCHMSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(oxetan-3-yloxy)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)OC1COC1 OAKZLEZKMVHSHC-LJQANCHMSA-N 0.000 claims 2
- OVKKJTHRZUCBSV-YQYDADCPSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(oxolan-3-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1COCC1 OVKKJTHRZUCBSV-YQYDADCPSA-N 0.000 claims 2
- FYPXPQSPRRZJCK-MRXNPFEDSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-[4-(trifluoromethyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C(F)(F)F FYPXPQSPRRZJCK-MRXNPFEDSA-N 0.000 claims 2
- FWDOVLGKHCXRFF-MRXNPFEDSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-pyrazol-1-ylpyrazolo[1,5-a]pyrimidine Chemical compound FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=CC=N2)=C(F)C=C1 FWDOVLGKHCXRFF-MRXNPFEDSA-N 0.000 claims 2
- ZXYOEGYYCHOXLT-CQSZACIVSA-N 5-[(2R)-2-(3,6-difluoropyridin-2-yl)pyrrolidin-1-yl]-3-(4-methylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound CC1=CN(N=C1)C1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=NC(F)=CC=C1F ZXYOEGYYCHOXLT-CQSZACIVSA-N 0.000 claims 2
- IFEYPPSMVUHFEX-LJQANCHMSA-N 5-[(2R)-2-(3,6-difluoropyridin-2-yl)pyrrolidin-1-yl]-3-[4-(5-methoxypyridin-3-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC=1C(=NC(=CC=1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C=NC=C(C=1)OC IFEYPPSMVUHFEX-LJQANCHMSA-N 0.000 claims 2
- NKOLSNLRDIPVJR-OAHLLOKOSA-N 5-[(2R)-2-(3-fluoro-6-methoxypyridin-2-yl)pyrrolidin-1-yl]-3-(4-methylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound COC1=CC=C(F)C(=N1)[C@H]1CCCN1C1=NC2=C(C=NN2C=C1)N1C=C(C)C=N1 NKOLSNLRDIPVJR-OAHLLOKOSA-N 0.000 claims 2
- CSNCCZUIDUOCAH-HXUWFJFHSA-N 5-[(2R)-2-(3-fluoropyridin-2-yl)pyrrolidin-1-yl]-3-[4-(5-methoxypyridin-3-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC=1C(=NC=CC=1)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C=NC=C(C=1)OC CSNCCZUIDUOCAH-HXUWFJFHSA-N 0.000 claims 2
- ZONJYFUIJJESDB-LJQANCHMSA-N 5-[(2R)-2-(3-fluoropyridin-2-yl)pyrrolidin-1-yl]-3-[4-(6-methoxypyridin-3-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC=1C(=NC=CC=1)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C=NC(=CC=1)OC ZONJYFUIJJESDB-LJQANCHMSA-N 0.000 claims 2
- MOMMUPHDQFGSST-CQSZACIVSA-N 5-[(2R)-2-(3-fluoropyridin-2-yl)pyrrolidin-1-yl]-3-[4-(trifluoromethyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC=1C(=NC=CC=1)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C(F)(F)F MOMMUPHDQFGSST-CQSZACIVSA-N 0.000 claims 2
- KHYNWYUCBXUNOD-JOCHJYFZSA-N 5-[1-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-4-yl]pyridine-3-carbonitrile Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C=NC=C(C#N)C=1 KHYNWYUCBXUNOD-JOCHJYFZSA-N 0.000 claims 2
- JODKEDGKZUWACK-MRXNPFEDSA-N 5-fluoro-N,N-dimethyl-6-[(2R)-1-[3-(4-methylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-5-yl]pyrrolidin-2-yl]pyridin-2-amine Chemical compound CN(C)C1=NC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C)C=N2)=C(F)C=C1 JODKEDGKZUWACK-MRXNPFEDSA-N 0.000 claims 2
- SLWZFZMCROXTBB-HXUWFJFHSA-N CC1=C(C(C)=NO1)C1=CN(N=C1)C1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1 Chemical compound CC1=C(C(C)=NO1)C1=CN(N=C1)C1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1 SLWZFZMCROXTBB-HXUWFJFHSA-N 0.000 claims 2
- RZDNAELBSZNRMA-GOSISDBHSA-N COC1=CC=C(C=N1)C1=CN(N=C1)C1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=NC(F)=CC=C1F Chemical compound COC1=CC=C(C=N1)C1=CN(N=C1)C1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=NC(F)=CC=C1F RZDNAELBSZNRMA-GOSISDBHSA-N 0.000 claims 2
- RGUPUVWKVSAUNC-LJQANCHMSA-N Cc1ncc(s1)-c1cnn(c1)-c1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F Chemical compound Cc1ncc(s1)-c1cnn(c1)-c1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F RGUPUVWKVSAUNC-LJQANCHMSA-N 0.000 claims 2
- ACOVPJBTZUDYQF-HSZRJFAPSA-N FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=C(C(=C1)C1=CC=CC=C1)C Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=C(C(=C1)C1=CC=CC=C1)C ACOVPJBTZUDYQF-HSZRJFAPSA-N 0.000 claims 2
- MEOFMFQYKXYPRU-OAQYLSRUSA-N FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=CC=NC=C1 Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=CC=NC=C1 MEOFMFQYKXYPRU-OAQYLSRUSA-N 0.000 claims 2
- IKECQRLAUKAHGG-HXUWFJFHSA-N FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=COC=C1 Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=COC=C1 IKECQRLAUKAHGG-HXUWFJFHSA-N 0.000 claims 2
- PKSYJTLRKVJVPW-OAQYLSRUSA-N FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C=NC=C(C=1)F Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C=NC=C(C=1)F PKSYJTLRKVJVPW-OAQYLSRUSA-N 0.000 claims 2
- SDNUDUXMVSBODP-HXUWFJFHSA-N FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)COCCOC Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)COCCOC SDNUDUXMVSBODP-HXUWFJFHSA-N 0.000 claims 2
- OQZKOMRUKNROFF-HXUWFJFHSA-N FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C(=O)N2CCOCC2)=C(F)C=C1 Chemical compound FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C(=O)N2CCOCC2)=C(F)C=C1 OQZKOMRUKNROFF-HXUWFJFHSA-N 0.000 claims 2
- QPSBIRQTQQJSAV-XMMPIXPASA-N FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C2=CC(OC3COC3)=CN=C2)=C(F)C=C1 Chemical compound FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C2=CC(OC3COC3)=CN=C2)=C(F)C=C1 QPSBIRQTQQJSAV-XMMPIXPASA-N 0.000 claims 2
- ADEQOCVYRHUSQD-HSZRJFAPSA-N FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C2=CC=C(OC3COC3)N=C2)=C(F)C=C1 Chemical compound FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C2=CC=C(OC3COC3)N=C2)=C(F)C=C1 ADEQOCVYRHUSQD-HSZRJFAPSA-N 0.000 claims 2
- SPKADCXPAOWIMB-HXUWFJFHSA-N FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C2=CN=CC=N2)=C(F)C=C1 Chemical compound FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C2=CN=CC=N2)=C(F)C=C1 SPKADCXPAOWIMB-HXUWFJFHSA-N 0.000 claims 2
- AYELOWZYMHZUKJ-HXUWFJFHSA-N FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C2=CN=NC=C2)=C(F)C=C1 Chemical compound FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C2=CN=NC=C2)=C(F)C=C1 AYELOWZYMHZUKJ-HXUWFJFHSA-N 0.000 claims 2
- LFCZCVITEGRJGK-LJQANCHMSA-N FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C3COCCC3=N2)=C(F)C=C1 Chemical compound FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C3COCCC3=N2)=C(F)C=C1 LFCZCVITEGRJGK-LJQANCHMSA-N 0.000 claims 2
- RZNNECCXIBSCGW-LJQANCHMSA-N FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2N=CC3=C2CCOC3)=C(F)C=C1 Chemical compound FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2N=CC3=C2CCOC3)=C(F)C=C1 RZNNECCXIBSCGW-LJQANCHMSA-N 0.000 claims 2
- OVXJBNOYWIFQPQ-LJQANCHMSA-N FC=1C(=NC(=CC=1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=CC=CC=C1 Chemical compound FC=1C(=NC(=CC=1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=CC=CC=C1 OVXJBNOYWIFQPQ-LJQANCHMSA-N 0.000 claims 2
- RAMBNCGOOPCUEY-OAHLLOKOSA-N FC=1C=CC(=NC=1[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C)NC Chemical compound FC=1C=CC(=NC=1[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C)NC RAMBNCGOOPCUEY-OAHLLOKOSA-N 0.000 claims 2
- LITYMJIPRJRKDH-CQSZACIVSA-N N-[(1R)-1-(2,5-difluorophenyl)ethyl]-3-[4-(6-methoxypyridin-3-yl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound FC1=C(C=C(C=C1)F)[C@@H](C)NC1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C=1C=NC(=CC=1)OC LITYMJIPRJRKDH-CQSZACIVSA-N 0.000 claims 2
- ZUSMIJRMTPRXTJ-OAHLLOKOSA-N N-methyl-3-(4-methylpyrazol-1-yl)-N-[(1R)-1-phenylethyl]pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound C1(=CN(N=C1)C1=C2N(N=C1)C=CC(N(C)[C@@H](C1=CC=CC=C1)C)=N2)C ZUSMIJRMTPRXTJ-OAHLLOKOSA-N 0.000 claims 2
- JYIMXKQKLPLRNQ-QGZVFWFLSA-N [1-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-4-yl]methanol Chemical compound C=1(C=NN(C=1)C1=C2N=C(N3[C@H](CCC3)C3=C(F)C=CC(F)=C3)C=CN2N=C1)CO JYIMXKQKLPLRNQ-QGZVFWFLSA-N 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- IVGGUXVGLNHZBK-MRXNPFEDSA-N 1-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]pyrazole-4-carboxamide Chemical compound NC(=O)C1=CN(N=C1)C1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1 IVGGUXVGLNHZBK-MRXNPFEDSA-N 0.000 claims 1
- UAXGJOWHWARXQB-MRXNPFEDSA-N 3-[4-(difluoromethyl)pyrazol-1-yl]-5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound FC(C=1C=NN(C=1)C=1C=NN2C=1N=C(C=C2)N1[C@H](CCC1)C1=C(C=CC(=C1)F)F)F UAXGJOWHWARXQB-MRXNPFEDSA-N 0.000 claims 1
- UCBNOPMQNGYPPJ-OAHLLOKOSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-(1,2,4-triazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CN=C1 UCBNOPMQNGYPPJ-OAHLLOKOSA-N 0.000 claims 1
- JFIPIPAKLBOSAP-QGZVFWFLSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-(4-methoxypyrazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)OC JFIPIPAKLBOSAP-QGZVFWFLSA-N 0.000 claims 1
- XSIYVAGMAVSONL-QGZVFWFLSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-(4-methylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound C=1(C=NN(C=1)C1=C2N=C(N3[C@H](CCC3)C3=C(F)C=CC(F)=C3)C=CN2N=C1)C XSIYVAGMAVSONL-QGZVFWFLSA-N 0.000 claims 1
- DPDYHALGWUOTEW-QGZVFWFLSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-(4-methylsulfonylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound CS(=O)(=O)C1=CN(N=C1)C1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1 DPDYHALGWUOTEW-QGZVFWFLSA-N 0.000 claims 1
- PBGNGMUNIXDIQJ-JOCHJYFZSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-(4-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=CC=CC=C1 PBGNGMUNIXDIQJ-JOCHJYFZSA-N 0.000 claims 1
- MSCILRPMEBTSMF-HXUWFJFHSA-N 5-[(2R)-2-(3-fluoropyridin-2-yl)pyrrolidin-1-yl]-3-(4-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound FC=1C(=NC=CC=1)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=CC(=C1)C1=CC=CC=C1 MSCILRPMEBTSMF-HXUWFJFHSA-N 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- QKVSHHHMLRSYER-OAHLLOKOSA-N C=1(C=NN(C=1)C1=C2N=C(N3[C@H](CCC3)C3=C(C=CC=N3)F)C=CN2N=C1)C Chemical compound C=1(C=NN(C=1)C1=C2N=C(N3[C@H](CCC3)C3=C(C=CC=N3)F)C=CN2N=C1)C QKVSHHHMLRSYER-OAHLLOKOSA-N 0.000 claims 1
- QTTPFSDNCKCDDU-GOSISDBHSA-N FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=C(C(=C1)C)C Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2N1N=C(C(=C1)C)C QTTPFSDNCKCDDU-GOSISDBHSA-N 0.000 claims 1
- IVGYEASQESFHHO-QGZVFWFLSA-N FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C#N)=C(F)C=C1 Chemical compound FC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C#N)=C(F)C=C1 IVGYEASQESFHHO-QGZVFWFLSA-N 0.000 claims 1
- 229910003827 NRaRb Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (15)
1. Spoj s formulom (IV)
[image]
ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat, naznačen time što:
X je H, (C1-C6) alkil, ili halogen;
X1 je H ili D;
Y je H, D, C1-C6 alkil, ili CN;
L je
[image]
-O(CR3R4)-(C6-C10) aril, -NR5-(CR3R4)-(C6-C10) aril, -O(CR3R4)-5- ili 6-eročlani heteroaril, ili
-NR5-(CR3R4)-5- ili 6- člani heteroaril, pri čemu su aril i heteroaril po izboru supstituirani s jednim ili više R6;
svaki R1 i R1' je neovisno H, (C1-C6) alkil, (C1-C6) alkoksi, (C1-C6) haloalkil, (C1-C6) haloalkoksi, halogen, ili -OH;
R2 je (C6-C10) aril ili 5- ili 6-eročlani heteroaril, pri čemu su aril i heteroaril po izboru supstituirani s jednim ili više R7;
R2' je H, D, (C1-C6) alkil, ili halogen;
svaki R3, R4 i R5 pri svakoj pojavi je neovisno H ili (C1-C6) alkil;
svaki R6 je neovisno pri svakoj pojavi (C1-C6) alkil, (C1-C6) alkoksi, (C1-C6) haloalkil, (C1-C6) haloalkoksi, ili halogen;
svaki R7 je neovisno pri svakoj pojavi (C1-C6) alkil, (C1-C6) alkoksi, (C1-C6) haloalkil, (C1-C6) haloalkoksi, ili halogen;
A je
[image]
Q je N ili CR9;
svaki od R8 i R9, pri svakoj pojavi, neovisno je H, halogen, cijano, (C0-C6)alkil-ORa, (C0-C6)alkil- NRaRb, (C0-C6)alkil-C(O)Ra, (C0-C6)alkil-P(O)RaRb , (C0-C6)alkil-S(O)pRa, NReC(O)Ra, ili NReS(O)2Ra, ili Rw,
ili R8 i R9, zajedno s atomima na koje su oni vezani, tvore 5- do 7-eročlani prsten koji po izboru sadrži jedan ili više heteroatoma odabranih od N, O, i S i po izboru supstituiran s jednim ili više RS1; svaki Rw neovisno je (C1-C6) alkil, (C1-C6) haloalkil, (C3-C8) cikloalkil, 3- do 8-eročlani heterocikloalkil, (C6-C10) aril, ili 5- do 10-eročlani heteroaril, svaki od kojih je po izboru supstituiran s jednim ili više RS2;
svaki od RS1 i RS2, pri svakoj pojavi, neovisno je H, halogen, cijano, (C1-C6) alkil, (C1-C6) haloalkil, (C0-C3)alkil-ORc, (C0-C3)alkil-NRcRd, C(O)ORc, ili C(O)NRcRd;
svaki od Ra, Rb, Rc, i Rd neovisno je Ri, (C3-C8) cikloalkil, 3- do 8-eročlani heterocikloalkil, (C0-C3)alkil-ORg, ili (C0-C3)alkil-NRgNRh,
ili Ra i Rb ili Rc i Rd zajedno s atomima na koje su oni vezani tvore 5- do 7-eročlani prsten koji po izboru sadrži jedan ili više heteroatoma odabranih od N, O, i S;
svaki od Re, Rf, Rg, Rh, Ri, i Rj neovisno je H, (C1-C6) alkil ili (C1-C6) haloalkil;
n je 0, 1, ili 2; i
p je 0, 1, ili 2.
2. Spoj prema patentnom zahtjevu 1, naznačen time što X je H, F, ili metil;
po izboru, X je H ili F; i
po izboru, X je H.
3. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time što R2 je 6-eročlani heteroaril po izboru supstituiran s jednim ili više R7; i po izboru, R2 je
[image]
pri čemu m je 0, 1, 2, 3, ili 4, po izboru, m je 0, 1, ili 2.
4. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time što R2 je (C6-C10) aril po izboru supstituiran s jednim ili više R7; po izboru, R2 je
[image]
pri čemu m je 0, 1, 2, 3, 4, ili 5, po izboru, m je 0, 1, ili 2.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu L je
[image]
ili -NR5-(CR3R4)-(C6-C10) aril, pri čemu aril je po izboru supstituiran s jednim ili više R6; i po izboru, L je
[image]
6. Spoj prema patentnom zahtjevu 5, naznačen time što R5 je H ili CH3; po izboru, R5 je H.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time što A je
[image]
i po izboru, A je
[image]
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što je svaki R9 neovisno 5- do 6-eročlani heterocikloalkil, 5 do 6-eročlani heteroaril, (C1-C3) alkil, ili RW;
po izboru, R9 je RW; i
po izboru, R9 je (C1-C6) haloalkil.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time što je svaki R8 neovisno 5- do 6-eročlani heterocikloalkil, 5- do 6-eročlani heteroaril, ili (C1-C3) alkil; po izboru, R8 je (C1-C3) alkil.
10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time što n je 0 ili 1; po izboru, n je 0.
11. Spoj prema patentnom zahtjevu 1, naznačen time što je spoj s formulom (V), (Va), (Vb), (Vc), (Vd), (VIa), (VIb), (VIc), (VIIa), (VIIb), (VIIc), (VIIIa), (VIIIb), ili (VIIIc):
[image]
[image]
[image]
ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat;
po izboru, spoj je s formulom (V), (Va), ili (Vc), ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat; i
po izboru, spoj je s formulom (Va) ili (Vc), ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat.
12. Spoj prema patentnom zahtjevu 1, naznačen time što je spoj odabran iz niza koji sadrži:
(R)-5-(2-(2,5-difluorfenil)pirolidin- 1-il)-3-(4-(trifluormetil)-1H-pirazol- 1-il)pirazolo[1,5-a]pirimidin (1-147);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-metil-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-148);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-fenil-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-149);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(3,4-dimetil-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-150);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(3-metil-4-fenil-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-151);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-152);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(pirazin-2-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-153);
(R)-5-(2-(3,6-difluorpiridin-2-il)pirolidin-1-il)-3-(4-metil-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-154);
(R)-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)metanol (1-155);
(R)-2-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)etan-1-ol (1-156);
(R)-4-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)-3,5-dimetil- izoksazol (1-157);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(1’-metil-1H,1'H-[4,4’-bipirazol]-1-il)pirazolo[1,5-a]pirimidin (1-158);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(piridin-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-159);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(piridin-4-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-160);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(5-metoksipiridin-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-161);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(tiofen-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-162);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(pirimidin-5-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-163);
(R)-5-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)-2-metiltiazol (I-164);
(R)-4-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)-1-metilpiridin-2(1H)-on (I-165);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(5-metoksi-3-metil-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-166);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(3-metoksi-5-metil-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-167);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(1H-1,2,4-triazol-1-il)pirazolo[1,5-a]pirimidin (1-168);
(R)-2-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)propan-2-ol (I-169);
(R)-1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-carbonitril (1-170);
(R)-3-(1H,1’H-[4,4’-bipirazoll-1-il)-5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin (1-171);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-metoksi-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-172);
(R)-1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-karboksamid (1-173);
(R)-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)dimetilfosfin oksid (1-174);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(3,6-dihidro-2H-piran-4-il)-1H-pirazol-1-il)pirazolo[1,5- a]pirimidin (I-175);
(R)-3-(4-(difluormetil)-1H-pirazol-1-il)-5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin (1-176);
(R)-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)dietilfosfin oksid (1-177);
(R)-2-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)-5-metil- 1,3,4-oksadiazol (I-178);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(oksetan-3-iloksi)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-179);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-((2-metoksietoksi)metil)-1H-pirazol-1-il)pirazolo[1,5- a]pirimidin (I-180);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(metilsulfonil)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-181);
(R)-5-(2-(3-fluorpiridin-2-il)pirolidin-1-il)-3-(4-metil-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-182);
(R)-2-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-2,4,6,7-tetrahidropirano[4,3-c]pirazol (I-183);
(R)-1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1,4,6,7-tetrahidropirano[4,3-c]pirazol (1-184);
(R)-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)(morfolino)metanon (1-185);
(R)-1-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)-N,N-dimetil- metanamin (I-186);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(tetrahidro-2H-piran-4-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-187);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(2,5-dihidrofuran-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-188);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(furan-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I- 189);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(5-fluorpiridin-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-190);
(R)-5-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[ 1,5-a]pirimidin-3-il)-1H-pirazol-4-il)nikotinonitril (1-191);
(R)-5-(2-(3-fluorpiridin-2-il)pirolidin-1-il)-3-(4-fenil-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-192);
(R)-5-(2-(3,6-difluorpiridin-2-il)pirolidin-1-il)-3-( 4-fenil-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-193);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(2-fluorpiridin-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-194);
(R)-N-metil-3-(4-metil-1H-pirazol-1-il)-N-(1-feniletil)pirazolo[1,5-a]pirimidin-5-amin (I-195);
(R)-3-(4-metil-1H-pirazol-1-il)-N-(1-feniletil)pirazolo[1,5-a]pirimidin-5-amin (I-196);
(R)-3-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)-1,1-dimetilurea (1-197);
(R)-3-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)-1,1-dimetilsulfonilurea (1-198);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(piridazin-4-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-199);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(6-metoksipiridin-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-200);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(4-metoksipiridin-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-201);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(2-metoksipiridin-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-202);
(R)-4-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)nikotinamid (1-203);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(3-metoksipiridin-4-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-204);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(3-fluorpiridin-4-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (1-205);
(R)-5-(2-(3,6-difluorpiridin-2-il)pirolidin-1-il)-3-(4-(5-metoksipiridin-3-il)-1H-pirazol-1-il)pirazolo[1,5- a]pirimidin (I-206);
(R)-5-(2-(3,6-difluorpiridin-2-il)pirolidin-1-il)-3-(4-(piridin-4-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-207);
1-(1-(5-((R)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)pirolidin-3-ol (I-208);
1-(1-(5-((R)-2-(3-fluorpiridin-2-il)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)pirolidin-3-ol (I-209);
5-((R)-2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(tetrahidrofuran-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-210);
(R)-5-(2-(3-fluorpiridin-2-il)pirolidin-1-il)-3-(4-(5-metoksipiridin-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-211);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(4,5-dihidrofuran-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-212);
(R)-5-(2-(3-fluorpiridin-2-il)pirolidin-1-il)-3-(4-(piridin-4-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I- 213);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(5-(oksetan-3-iloksi)piridin-3-il)-1H-pirazol-1-il)pirazolo[1,5- a]pirimidin (I-214);
(R)-5-(2-(3-fluorpiridin-2-il)pirolidin-1-il)-3-(4-(trifluormetil)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I- 215);
(R)-5-(2-(3-fluor-6-metoksipiridin-2-il)pirolidin-1-il)-3-(4-metil-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-216);
(R)-5-fluor-N,N-dimetil-6-(1-(3-(4-metil-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin-5-il)pirolidin-2-il)pirid- in-2-amin (I-217);
(R)-5-fluor-N-metil-6-(1-(3-(4-metil-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin-5-il)pirolidin-2-il)piridin-2-amin (I-218);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(6-fluorpiridin-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-219);
(R)-N-(1-(2,5-difluorfenil)etil)-3-(4-(6-metoksipiridin-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin-5-amin (I-220);
(R)-5-(2-(3,6-difluorpiridin-2-il)pirolidin-1-il)-3-(4-(6-metoksipiridin-3-il)-1H-pirazol-1-il)pirazolo[1,5- a]pirimidin (I-221);
(R)-5-(2-(3-fluorpiridin-2-il)pirolidin-1-il)-3-(4-(6-metoksipiridin-3-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-222);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(6-(oksetan-3-iloksi)piridin-3-il)-1H-pirazol-1-il)pirazolo[1,5- a]pirimidin (I-223);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(2-metoksipirimidin-5-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-224);
(R)-1-(1-(5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-1H-pirazol-4-il)etan-1-on (I- 225); i
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(metoksimetil)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidin (I-226).
13. Spoj prema patentnom zahtjevu 1, naznačen time što je spoj odabran od:
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(trifluormetil)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidina (I-147);
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(pirimidin-5-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidina (I- 163);
(R)-3-(1H,1’H-[4,4’-bipirazol]-1-il)-5-(2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidina (I-171);
(R)-5-(2-(3,6-difluorpiridin-2-il)pirolidin-1-il)-3-(4-(piridin-4-il)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidina (I-207); i
(R)-5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(4-(metoksimetil)-1H-pirazol-1-il)pirazolo[1,5-a]pirimidina (I-226).
14. Farmaceutski pripravak, naznačen time što sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 13, te farmaceutski prihvatljiv nosač.
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 13, ili njegova farmaceutski prihvatljiva sol, za upotrebu za:
(i) inhibiranje Trk kinaze ili fuzije Trk kinaze kod subjekta; ili
(ii) liječenje bolesti ili poremećaja; po izboru pri čemu je bolest ili poremećaj:
(a) posredovan s Trk kinazom ili fuzijom Trk kinaze; ili
(b) rak.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762599490P | 2017-12-15 | 2017-12-15 | |
PCT/US2018/065187 WO2019118584A1 (en) | 2017-12-15 | 2018-12-12 | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer |
EP18836977.1A EP3724191B9 (en) | 2017-12-15 | 2018-12-12 | 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220464T1 true HRP20220464T1 (hr) | 2022-05-27 |
Family
ID=65139120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220464TT HRP20220464T1 (hr) | 2017-12-15 | 2018-12-12 | Derivati 5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(1h-pirazol-1-il)pirazolo[1,5-a]pririmidina i srodni spojevi kao inhibitori trk kinaze za liječenje raka |
Country Status (24)
Country | Link |
---|---|
US (3) | US11230546B2 (hr) |
EP (2) | EP3724191B9 (hr) |
JP (1) | JP7321183B2 (hr) |
KR (1) | KR20200099557A (hr) |
CN (1) | CN111819179B (hr) |
AU (1) | AU2018383571B2 (hr) |
BR (1) | BR112020011775A2 (hr) |
CA (1) | CA3084814A1 (hr) |
DK (1) | DK3724191T3 (hr) |
EA (1) | EA202091475A1 (hr) |
ES (1) | ES2908773T3 (hr) |
HR (1) | HRP20220464T1 (hr) |
HU (1) | HUE059313T2 (hr) |
IL (1) | IL275059B2 (hr) |
LT (1) | LT3724191T (hr) |
MX (1) | MX2020006293A (hr) |
PL (1) | PL3724191T3 (hr) |
PT (1) | PT3724191T (hr) |
SA (1) | SA520412192B1 (hr) |
SG (1) | SG11202005237SA (hr) |
SI (1) | SI3724191T1 (hr) |
TW (1) | TW201936194A (hr) |
WO (1) | WO2019118584A1 (hr) |
ZA (2) | ZA202003483B (hr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201936194A (zh) | 2017-12-15 | 2019-09-16 | 美商金字塔生技公司 | 肌旋蛋白激酶抑制劑 |
GB201813791D0 (en) * | 2018-08-23 | 2018-10-10 | Benevolental Bio Ltd | Organic compounds |
CN111718350B (zh) * | 2019-03-19 | 2021-04-13 | 华中师范大学 | 吡唑取代的吡唑并嘧啶化合物和药物组合物及其应用 |
AU2020242735B2 (en) * | 2019-03-19 | 2022-12-01 | Central China Normal University | Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor |
CN111848626B (zh) * | 2019-04-30 | 2021-11-30 | 江苏柯菲平医药股份有限公司 | Trk激酶抑制剂及其用途 |
CN112979654B (zh) * | 2019-12-16 | 2024-03-19 | 赛诺哈勃药业(成都)有限公司 | 杂芳基稠环化合物、其制备方法及应用 |
CN115515591A (zh) * | 2020-04-15 | 2022-12-23 | 派拉米德生物科学公司 | 用于制备酪氨酸受体激酶抑制剂的方法 |
CN114437077B (zh) * | 2020-11-04 | 2024-01-30 | 浙江同源康医药股份有限公司 | 用作激酶抑制剂的化合物及其应用 |
CN114437075A (zh) * | 2020-11-03 | 2022-05-06 | 上海瑶琪生物科技有限公司 | 用作ntrk激酶抑制剂的化合物及其应用 |
KR102541026B1 (ko) * | 2020-11-11 | 2023-06-12 | 주식회사 한독 | Trk 억제제 화합물의 제조 방법 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009140128A2 (en) * | 2008-05-13 | 2009-11-19 | Irm Llc | Compounds and compositions as kinase inhibitors |
HUE057625T2 (hu) * | 2008-10-22 | 2022-05-28 | Array Biopharma Inc | TRK kináz inhibitor szubsztituált pirazolo[1,5-a]pirimidin vegyületek |
PE20131197A1 (es) | 2008-10-31 | 2013-11-06 | Genentech Inc | Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen |
US8591943B2 (en) | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
WO2012034095A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012125668A1 (en) * | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
US20140288043A1 (en) | 2013-03-19 | 2014-09-25 | Genentech, Inc. | Pyrazolopyridine compounds |
WO2015143652A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
FR3029769A1 (fr) * | 2014-12-10 | 2016-06-17 | Tornier Sa | Kit pour une prothese d'epaule |
CA2971024C (en) * | 2014-12-15 | 2023-09-26 | Handok Inc. | Fused ring heteroaryl compounds and their use as trk inhibitors |
AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
JP6475084B2 (ja) | 2015-05-21 | 2019-02-27 | 臼井国際産業株式会社 | トルクセンサ用シャフトの製造設備およびその製造方法 |
TW201936194A (zh) | 2017-12-15 | 2019-09-16 | 美商金字塔生技公司 | 肌旋蛋白激酶抑制劑 |
CN115515591A (zh) | 2020-04-15 | 2022-12-23 | 派拉米德生物科学公司 | 用于制备酪氨酸受体激酶抑制剂的方法 |
-
2018
- 2018-12-12 TW TW107144769A patent/TW201936194A/zh unknown
- 2018-12-12 KR KR1020207020360A patent/KR20200099557A/ko not_active Application Discontinuation
- 2018-12-12 EP EP18836977.1A patent/EP3724191B9/en active Active
- 2018-12-12 US US16/772,253 patent/US11230546B2/en active Active
- 2018-12-12 WO PCT/US2018/065187 patent/WO2019118584A1/en active Application Filing
- 2018-12-12 MX MX2020006293A patent/MX2020006293A/es unknown
- 2018-12-12 ES ES18836977T patent/ES2908773T3/es active Active
- 2018-12-12 CA CA3084814A patent/CA3084814A1/en active Pending
- 2018-12-12 HR HRP20220464TT patent/HRP20220464T1/hr unknown
- 2018-12-12 CN CN201880080978.XA patent/CN111819179B/zh active Active
- 2018-12-12 IL IL275059A patent/IL275059B2/en unknown
- 2018-12-12 EA EA202091475A patent/EA202091475A1/ru unknown
- 2018-12-12 AU AU2018383571A patent/AU2018383571B2/en active Active
- 2018-12-12 JP JP2020551775A patent/JP7321183B2/ja active Active
- 2018-12-12 EP EP22152688.2A patent/EP4053128A1/en active Pending
- 2018-12-12 DK DK18836977.1T patent/DK3724191T3/da active
- 2018-12-12 LT LTEPPCT/US2018/065187T patent/LT3724191T/lt unknown
- 2018-12-12 BR BR112020011775-7A patent/BR112020011775A2/pt unknown
- 2018-12-12 PL PL18836977T patent/PL3724191T3/pl unknown
- 2018-12-12 HU HUE18836977A patent/HUE059313T2/hu unknown
- 2018-12-12 PT PT188369771T patent/PT3724191T/pt unknown
- 2018-12-12 SG SG11202005237SA patent/SG11202005237SA/en unknown
- 2018-12-12 SI SI201830632T patent/SI3724191T1/sl unknown
-
2020
- 2020-06-10 ZA ZA2020/03483A patent/ZA202003483B/en unknown
- 2020-06-13 SA SA520412192A patent/SA520412192B1/ar unknown
-
2021
- 2021-11-23 US US17/533,954 patent/US20220235055A1/en not_active Abandoned
-
2022
- 2022-05-27 ZA ZA2022/05900A patent/ZA202205900B/en unknown
- 2022-12-08 US US18/078,087 patent/US11739096B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220464T1 (hr) | Derivati 5-(2-(2,5-difluorfenil)pirolidin-1-il)-3-(1h-pirazol-1-il)pirazolo[1,5-a]pririmidina i srodni spojevi kao inhibitori trk kinaze za liječenje raka | |
JP2021506954A5 (hr) | ||
ES2778700T3 (es) | Nuevos derivados de piperidinilo sustituidos con (hetero)arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
JP6526167B2 (ja) | 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物 | |
US10377760B2 (en) | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | |
JP5972942B2 (ja) | Atrキナーゼの阻害剤として有用な化合物 | |
KR101892989B1 (ko) | 헤테로아릴 화합물 및 이의 용도 | |
JP2018087213A (ja) | Atrキナーゼ阻害剤として有用な化合物 | |
AU2013347538B2 (en) | Purine inhibitors of human phosphatidylinositol 3-kinase delta | |
JP2015522002A5 (hr) | ||
SI3177619T1 (en) | 2- (morpholin-4-yl) -1,7-naphthyridines | |
SI3083586T1 (en) | The new carboxamides, the process of their manufacture, the pharmaceutical preparations they contain and their use for the manufacture of medicinal products | |
RU2018142987A (ru) | Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m4 | |
KR20130038420A (ko) | 브루톤 티로신 키나아제의 억제제 | |
CA2921959A1 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
JP2009536651A5 (hr) | ||
HRP20220468T1 (hr) | Novi derivati izoksazolil etera kao gaba a alpha5 pam | |
EP3268358A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
US20160355504A1 (en) | Heteroaryl inhibitors of sumo activating enzyme | |
JPWO2019118584A5 (hr) | ||
TW202241889A (zh) | 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑 | |
OA17140A (en) | Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof |